Quintiles Library

Featured Podcast

The Friday Podcast: Direct-to-Patient Registries
...
Show Filters
Fact Sheet
クインタイルズの拡大RBMソリューションであるDTE (Data-driven Trial Execution)...
Read More
Brochure
クインタイルズの拡大RBMソリューションであるDTE (Data-driven Trial Execution)...
Read More
Fact Sheet
Bringing a new therapy to market is a complex process and it becomes even more challenging in the area of oncology. With an expected increase in people diagnosed with cancer, the budget of the NHS in the UK will be challenged in the future. However, there are ways for pharmaceutical companies to get new innovative therapies to market while at the same support the NHS in managing their budget. Read our factsheet and learn how localized solutions could help you improve patient access to new treatments, improve care pathways and demonstrate the real value of your...
Read More
Video 04:00
In 2009, Lindsey Elsaesser gave birth to a baby girl, Evie. But even before Evie was born, her story was unlike most. She was born with a rare genetic condition called hypophosphatasia (HPP), which inhibits affects the growth of bones and teeth. Here, Lindsey shares how Evie’s participation in a clinical trial provided her with hope for a brighter, healthier future. This is the player to use for single videos on Q.com ...
White Paper
Immunotherapy – using small molecules and biologics that provide therapeutic benefit by focusing the capabilities of the immune system on the tumor – promises to transform cancer care, having already shown striking patient responses. This paper provides an overview of the clinical immunotherapy landscape and offers goals and cautions to inform the development of therapies that enlist the power of the immune system to attack lethal and resistant forms of cancer. Authors: Brad Smith, Ph.D., Vice President of Translational Medicine, Quintiles  Chris A. Learn, Ph.D., PMP, Senior Clinical Project Manager, Quintiles  Eric Groves, MD, Ph.D., Vice President, Center for Integrated Drug Development,...
Explore More
Fact Sheet
Biosimilars are highly similar- but more affordable- successors to biologic drugs whose patents have expired. Unlike generics, biosimilars are not exact copies of originators because the manufacturing process of these large, complex molecules is too difficult to replicate precisely. For this reason, biosimilars require comprehensive evaluation to gain regulatory...
Read More
Press Release
SINGAPORE – 25 May 2015 – To help Asia-Pacific emerging biopharmaceutical companies achieve their growth aspirations, Quintiles today launched a new solution set tailored to meet the needs of emerging companies in the world’s most diverse and dynamic healthcare market. “Asia-Pacific is poised to become the world’s next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines,” said Senior Vice President Ross Horsburgh, M.D., Quintiles Head of Clinical Development, Asia-Pacific.  “These companies face formidable challenges as they look to expand into markets or therapeutic areas in which they may have limited or no experience.   “From start-ups to larger emerging players, our Asia-Pac solution is designed to improve their probability...
Read More
Fact Sheet
Selecting the right development partner is a balancing act. Do you want a local partner or one with access to extensive global resources? Broad or focused expertise? High touch or high tech? Low cost or high value? With the Quintiles Asia Pacific Emerging Biopharma Solution, you no longer have to compromise. Working on more than 60 studies for more than 45 Asia Pacific emerging biopharma customers since 2011, we’ve learned about your distinct challenges firsthand. And we’ve incorporated customer feedback to tailor a solution focused on your...
Read More
Podcast
Having just recognized International Clinical Trials Day, Jennifer Byrne from PMG Research discusses the numerous benefits of clinical trial...
Scientific Poster
Using simulation and data from a real-world trial we show that this effect is not trivial and complicates the interpretation of κ changes in the interpretation of reader performance, which, admittedly can change because of a multitude of...
Explore More
Video 02:44
Immunotherapy – using small molecules and biologics that provide therapeutic benefit by focusing the capabilities of the immune system on the tumor – promises to transform cancer care, having already shown striking patient responses. In this video, Phil Breitfeld, vice president and global head of the Quintiles Therapeutic Centers of Excellence, explores how immunotherapies could be used in real-world settings – alone or in combination with existing therapies – to improve cancer patients’ outcomes. This is the player to use for single videos on Q.com ...
Video 02:36
By 2025, we expect that sophisticated genomics-based tools will have transformed cancer care. In this video, Phil Breitfeld, vice president and global head of the Quintiles Therapeutic Centers of Excellence, discusses the history of genomics in oncology research and how this science is leading us to new ways of treating cancer. This is the player to use for single videos on Q.com ...
Video 03:36
Immunotherapy – using small molecules and biologics that provide therapeutic benefit by focusing the capabilities of the immune system on the tumor – promises to transform cancer care, having already shown striking patient responses. In this video, Phil Breitfeld, vice president and global head of the Quintiles Therapeutic Centers of Excellence, discusses some of the latest developments in immunotherapy for oncology. This is the player to use for single videos on Q.com ...
Video
Discover how Quintiles' Site and Patient Network group is fostering relationships, leveraging technology, and engaging patients.    This is the player to use for single videos on Q.com...
Press Release
RESEARCH TRIANGLE PARK, N.C. – May 20, 2015 – Quintiles CEO Tom Pike will present at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015 in New York City at the Grand Hyatt New York. The Quintiles presentation will begin at 11:30 a.m. (EDT). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 33,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2014’s top-75...
Read More
Presentation
During this webinar, Quintiles experts Eric Faulkner, MPH, Practice Leader, Emerging Technology Value Demonstration, Access & Commercialization and Kathryn Starzyk, Senior Director of Epidemiology, discuss new opportunities for rare diseases, how generating the right evidence can help you meet increasing multi-stakeholder demands, incorporating the patient voice into your research and delivering value at every step of the research process. Authors: Eric Faulkner, MPH, Practice Leader, Emerging Technology Value Demonstration, Access & Commercialization and Kathryn Starzyk, Senior Director of...
Explore More
Press Release
RESEARCH TRIANGLE PARK, NC – May 19 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Of the total shares sold in the offering, Quintiles repurchased 3,855,050 shares from the underwriters at a price of $64.85 per share, which is the same as the price per share paid to the Selling Shareholders by the underwriters. Quintiles did...
Read More
Media Coverage
In this article, Stella Blackburn discusses work conducted by the Innovative Medicines Initiative (IMI) and the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium), led by the European Medicines Agency.  The study looked at whether it’s possible to collect data directly from pregnant women without the intervention of healthcare professionals. The article was published in April 2015 by The Pregnancy & Medicine Initiative, which aims to raise awareness and help address the information vacuum concerning the use of medicines and medical treatment in pregnancy. Visit...
Read More